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Let the consumer decide? The regulation of
commercial genetic testing
Dr Mairi Levitt University of Central Lancashire, Preston
Abstract
Objectives—The development of predictive genetic
tests provides a new area where consumers can gain
knowledge of their health status and commercial
opportunities. “Over-the-counter” or mail order genetic
tests are most likely to provide information on carrier
status or the risk of developing a multifactorial disease.
The paper considers the social and ethical implications
of individuals purchasing genetic tests and whether
genetic information is diVerent from other types of
health information which individuals can obtain for
themselves.
Design—The discussion is illustrated by findings from
a questionnaire survey of university students as
potential consumers. Topics covered included what
health tests they had already used, expectations of
genetic tests, willingness to pay, who should have access
to the results and whether there need to be restrictions
on such tests.
Sample—Six hundred and fifteen first-year students
in the universities of Leuven, CardiV, Central
Lancashire, Vienna and Nijmegen studying either
medicine or a non-science subject.
Results—Students were enthusiastic about genetic tests
and had high expectations of their accuracy and
usefulness but most thought they should be available
through the health service and a minority thought that
some tests, for example for sex selection, should not be
available at all. There were few diVerences in responses
by sex or subject of study but some by country. The
paper also considers ethical and social issues outside the
scope of a questionnaire survey of this type.
Conclusion—To address some of these issues the sale
of genetic tests to individuals can be made subject to
ethical guidelines or codes of practice, for example to
protect vulnerable groups, but there are fundamental
social and ethical questions which such guidelines
cannot address.
(Journal of Medical Ethics 2001;27:398–403)
Keywords: Genetic tests; European; commercialisation
Health as lifestyle
Health education has made people increasingly
aware of all kinds of health risks. Lifestyles, food,
drinks, additives and chemicals are risk factors
given media attention. Students, in the study
discussed below, were asked to rate a list of factors
in terms of their importance for maintaining health.
Three of the first four factors they chose were
things over which the individual might be thought
to have control: diet, exercise and type of work, the
fourth was infections. The individual expects, and
is expected, to be proactive in health lifestyle in
contrast to a fatalistic view of health and illness. It
might seem that genetic makeup is outside the per-
son’s control but knowing your genetic risk is
becoming another task for the responsible indi-
vidual. The focus on individual responsibility and
control over health provides the right social climate
for “over the counter” testing as a way of exercising
this responsibility as a rational and autonomous
individual.
A study of potential users
Discussion of some of the ethical and social issues
raised by over the counter tests will be illustrated by
data from a pilot study carried out among a group
of potential personal users. A questionnaire study
of attitudes cannot, however, cover all the ethical
and social issues, particularly those looking at fun-
damental questions about priorities in health care
and the distribution of limited resources. The study
used a sample of students who were chosen as likely
to be among the first users of genetic test kits
because of their future occupations and earning
capacity. It was decided to give out questionnaires
to a whole first-year group taking medicine and
another group taking a non-medical, non-science
subject. Six hundred and fifteen university students
taking first-year courses completed questionnaires
in English, which were given out to all students
attending a lecture. The questions were mainly
closed, with space for comments. Forty-four per
cent were medical students and the rest were
studying philosophy, law or social science. The
majority were from Belgium and the UK, with a
smaller number from the Netherlands and Austria.1
Just over half were female and 90 per cent were in
the age group 18-25 years. The reason for the high
numbers in Belgium was that the response rate was
100 per cent because the questionnaires were given
out and taken in during a large first-year lecture
course. In the other countries the response rate was
around a third because students were given the
questionnaires during a lecture and asked to bring
them back. The responses may not therefore be
typical even of the full student group, except in
Belgium. The data are simply used, however, to
provide comment on issues raised by genetic testing
and it was found that on most issues there was
agreement between countries, between men and
women and between medical and non-medical stu-
dents.
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Summary of questions
Students were presented with two groups of
statements giving diVerent opinions on genetic
research and testing and asked whether they agreed
or disagreed with each (16 statements in all). These
were balanced in terms of enthusiasm for and
reservations about testing; for example: “I want to
know about testing for my partner and me, to see if
our children might be born with a genetic disorder”
and “I would only want to be tested for genetic dis-
eases which can be treated”. Belgium and the UK
gave similar answers and were enthusiastic about
testing. For example, “I want to know as much as
possible about any genetic disease I might de-
velop”: 69 per cent of Belgium and 71 per cent of
UK students agreed, with no sex diVerence.
However, the percentage agreeing that “there is too
much emphasis on genes as causes of disease rather
than the environment in which we live” was 57 per
cent overall, highest in the UK at 62 per cent. Stu-
dents were given a list of health care tests including
genetic tests and asked if they had had the test,
whether they had bought it themselves, might be
interested in buying it, were not interested in it or
had never heard of it. They were also asked where
these tests should be available (for example, for
individuals to buy, through the health service/
family doctor, or not at all). They were asked
whether they would be willing to pay for a test for a
breast cancer mutation for themselves; whether
they would encourage their partner to do so; the
maximum amount they would pay; whether they
would pay extra for counselling, and to give the
reasons for their answers in open questions.
Students were asked whether they thought there
needed to be restrictions on genetic testing and, if
so, what they should be; a specific question on the
genetic testing of currently healthy children was
included. Students were asked whether a person
with an unfavourable test result had a duty to tell
anyone. They were asked to rate their concerns
about tests provided by their national health service
and by private companies. It was thought students
might be much more concerned about the quality
of tests provided by private companies as opposed
to their national health service, but this was only
evident in the case of safeguards for children when
tests were provided privately, and among the UK
sample, who were generally more concerned about
non-National Health Service (NHS) tests. Stu-
dents were concerned about accuracy, confiden-
tiality, the availability of advice and that the limita-
tions of tests should be explained. A separate
question asked how accurate they would expect
diVerent types of genetic tests to be, ie for carrier
status (term explained), for a late onset disorder,
and prenatal screening.
Commercial health tests
Individuals in Britain can already buy health tests
to measure blood pressure, cholesterol, pregnancy,
diabetes and fertility. Mail order genetic tests
include carrier status for cystic fibrosis and a pater-
nity test which uses a cheek swab from father and
child. Newspaper advertisements for the paternity
test from the DNA testing agency, Keston, Kent,
read: “Whose child is it? Are you really the father?’2
In the US tests marketed directly to the public
include tests for susceptibility genes for breast and
ovarian cancer (BRCA1 and 2) and genetic predis-
position to cardiovascular disease; these are availa-
lbe from from Myriad Genetics, Salt Lake City. A
test for HIV is available from Home Access Health
Corporation.3 Small numbers of students in the
sample had bought tests for cholesterol level, blood
pressure and pregnancy but more had been tested
for the first two within the health service. The few
who had taken genetic tests had been tested within
their national health service, most for cystic fibrosis
carrier status (three per cent of the sample).
It is diYcult to estimate demand when the ques-
tion is hypothetical but a majority of students
reported that they would be willing to pay for a test
for a breast cancer mutation or would encourage
their partner to do so: 66 per cent of men and 62
per cent of women. Most would only be willing to
pay small amounts, 57 per cent named an amount
under 50 euros ($US 44), but for some this
reflected a lack of money rather than a low priority
for tests. One student wrote: “I would have to
decide whether to eat or buy the test”, while
another would pay “whatever it costs” because
“health has no price”. In an open question most of
those wanting the test said it was “best to know” so
that they would know how to avoid risks and have a
better chance of treatment or a cure. Breast cancer
was chosen as an example of a well-known
multifactorial disease but students may well have
overestimated the genetic component. Overall 15
per cent wrote to the eVect that it was “best not to
know”. Most of those answering would be willing to
pay extra for counselling if the test result was posi-
tive but a substantial minority would not, from 25
per cent in Belgium to 47 per cent in Austria. The
Austrian sample were on average older than the
Belgium sample and fewer older people as well as
fewer women were prepared to pay extra for coun-
selling, and the amounts they were willing to pay
were smaller. Overall 51 per cent were willing to pay
40 euros ($US35) or less for counselling. The ben-
efits expected (by 91 per cent of those answering)
were more information, a risk analysis, advice on
the best course of action and/or mental support.
Responses, included, for example: “Information
about the test and the best course of action”; “a
clear summary of results, relief and guidance”.
Are genetic tests diVerent?
It can be argued that there are no concerns, or no
new concerns, surrounding genetic tests as opposed
to other types of over the counter tests. In support
of this view the following arguments can be made:
v Why should we be concerned about genetic tests
when other self tests are available without regula-
tion? As the president of Myriad Genetics’s labo-
ratory said: “there’s really no diVerence between a
blood cholesterol test and a genetic test. No one
has given me a good reason why this type of test
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would require FDA oversight, [in the states]
whereas others do not.”4
v Commercial companies will only market tests
which people want to buy, if there is no market for
them they will not be produced. People should be
free to make up their own minds. As a spokesman
for the DNA Testing Agency is reported to have
said: “We are giving people the opportunity to do
private testing...”.5
v Commercial testing can fill gaps in provision
which cannot be met by public funding. The
European Diagnostic Association, commenting
on the ethical issues raised in the draft report on
this research wrote: “Industry believes it has an
increasingly important role in delivering health
care products and to a certain extent services
where public funding is not available or is
inadequate to meet patient demand”.
v It is important for individuals/families to have the
opportunity to be informed. The Genetic Interest
Group argues that genetic services oVer people
“the potential to acquire information about their
genetic make up ... though it may be bad news,
allows them to plan out their lives and make
informed reproductive decisions”.6 The group
criticises the cautious approach to genetic testing
of children in the Clinical Genetics Society report
as “overly concerned with psychological conse-
quences”.7
v There are always people who are frightened by
new technology, fuelled by media hype, but soon
it becomes routine and accepted like test tube
babies born through IVF. This point was made in
the focus groups on cloning run by the Wellcome
Trust.8
These arguments will be considered in more detail
and illustrated, where relevant, with information
from the students’ responses to the questionnaire.
WHY SHOULD WE BE CONCERNED ABOUT GENETIC
TESTS WHEN OTHER SELF TESTS ARE AVAILABLE
WITHOUT REGULATION?
This raises the issue of whether genetic technology
and the information it reveals is diVerent from other
health technology and information, and diVerent in
such a way that it has to be surrounded by special
restrictions to protect the public. It is necessary to
distinguish between types of genetic test. Diagnos-
tic tests will make a definite explanation of a current
condition, when the individual is already displaying
symptoms, or of carrier status for a recessive disor-
der such as cystic fibrosis (although in the case of
cystic fibrosis a test will be for the most common
mutations so can never achieve a 100 per cent
exclusion of a carrier status). Other tests will
predict a future condition before any symptoms
appear. It can be predicted that a newborn boy will
develop Duchenne muscular dystrophy and will
begin to show the symptoms in infancy. Genetic
tests may reveal a predisposition/susceptibility to a
disorder and can be used to calculate the risk of
developing breast or ovarian cancer, cardiovascular
disease or Alzheimer’s. There are more commercial
possibilities in tests for multifactorial conditions
such as these because they will be more common
and there is the potential to develop drugs to treat
the conditions. It is the treatments rather than the
test kits, which will generate profits.
Among these diVerent types of tests those which
diagnose an existing condition or carrier status may
seem least problematic, but when oVered over the
counter there is no control over who is being tested
or that person’s particular situation. A parent might
test a child or a pregnant woman might test herself
and her partner. Samples may be collected secretly
and sent for testing without the subject’s knowl-
edge, for example, hair collected from a hairbrush
as a source for paternity testing. The same test will
have diVerent implications depending on the
circumstances. In the case of child testing it takes
away the child’s right not to know about late onset
disorders such as diabetes. To ask why genetic tests
need regulation when cholesterol testing does not
implies that both are unproblematic, but perhaps
there should be more concern about cholesterol
testing, particularly in children, rather than less
concern about genetic tests.9
Two-thirds of the students wanted to know about
any genetic disorder they, their partner or unborn
children might develop but were less sure about
testing children for a disorder they might develop
later, with only one third in favour. The students
from the Netherlands were consistently against
parents testing their children. Students were
divided 50:50 on whether they would want to be
tested for untreatable disorders. They were asked if
any groups needed special protection when genetic
tests could be purchased by individuals and 96 per
cent chose at least one group. The top four groups
needing protection in order of choice were the same
for medical and non-medical students in all
countries:
1. Employees from employers: 69%;
2. Mentally handicapped people whose relatives
want them tested: 66%;
3. Unborn children: 61%, and
4. Children and adolescents whose parents want to
have them tested: 61%.
Students were asked what sort of protection would
be needed for the groups they had selected and then
to rate what, in their opinion, were the most impor-
tant forms of protection. The top two choices in
each country were that tests should be available
only through health professionals and there should
be government regulation; these were closely
followed by European regulation. Although want-
ing information for themselves students saw the
need for protection when those involved were not of
equal power and status: employees and employers,
mentally handicapped adults and their relatives,
children and parents.
COMMERCIAL COMPANIES WILL ONLY MARKET TESTS
WHICH PEOPLE WANT TO BUY
Commercial companies know that demand can be
generated but the consequences may be more seri-
ous than generating a market for Teletubbies or
designer trainers. Demand can be manipulated
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through the way information is oVered. If a test is
simply carried out routinely, like the phenylketonu-
ria (PKU) test for newborn babies, then an uptake
of around 100 per cent can be achieved. Uptake can
be gradually reduced by putting extra steps or
obstacles on the path to a test, for example, a card
to be returned before an appointment is made, pre-
test counselling and a waiting period. This was
illustrated in a pilot screening programme among
newborn boys in Wales for Duchenne muscular
dystrophy.10 The type of information with which
potential patients are provided is also important.
Information on new tests for the general public and
in the media tends to be positive, reflecting the
views of the researchers and making claims about
improved treatment or cures “soon”. However, the
Huntington’s gene discovered in 1993 has not yet
led to better treatment and current treatment for
sickle cell anaemia was developed before the gene
was identified. Multiplex testing, which oVers
packages of tests for diVerent kinds of conditions in
a single session, will further complicate the giving of
pretest information and the obtaining of informed
consent.11
The emphasis is on individual choice and
informed consent but the most important variable
in take-up rates for genetic testing is the way it is
oVered. The control oVered to the public is in any
case limited: they can take or reject a test but they
cannot decide what test services ought to be devel-
oped in the first place. The public are not expected
to argue that some tests should not be available at
all.
COMMERCIAL TESTING CAN FILL GAPS IN PROVISION
WHICH CANNOT BE MET BY PUBLIC FUNDING
It is the view of the industry that commercial test-
ing can fill gaps in provision which cannot be met
by public funding. A spokesman from a company
marketing cystic fibrosis testing kits by mail order
said: “There will be a growing demand from people
wanting to learn about their genetic make-up. The
NHS is already overstretched and GPs are not nec-
essarily experts in genetics, the private sector will
siphon oV demand”.12
There is concern that there will be greater health
inequality if some tests with health benefits are only
available to those who can pay. An alternative view
is that tests may be oVered which are not medically
indicated, have no therapeutic or preventive
options, do not test for a serious disorder and do
not oVer adequate certainty, in which case those
who cannot aVord them could be better oV! Either
way, commercial testing is likely to put a burden on
the health system rather than fill the gaps because
the test is only the beginning. If tests are available
over the counter public awareness of tests will
increase along with demand for them, whether they
are beneficial or not. Once people have had a
genetic test the NHS may be left to pick up the
pieces. In the UK patients will probably go straight
to their general practitioner (GP) for more
information, as 93 per cent of UK students in the
sample wrote that they would. It is likely that they
would be referred to their regional genetics centre
and perhaps retested if the status of the first test was
uncertain.13 Individuals, including children, will
present who would not have been tested for the
specific condition in the NHS or who would have
decided not to be tested if they had received pretest
counselling. Even those with a favourable result
may seek a second opinion from a trusted source.
The gap in provision referred to by the industry
may therefore be there for valid reasons. At the
moment resources are concentrated on genetic
testing for specific groups, for example, those with
a family history of a serious genetic disorder who
request preimplantation or prenatal testing, or
where diagnosis would aid treatment. There are
gaps in health provision which would benefit more
people’s health if they could be filled than
extending genetic testing, for example social and
environmental measures to improve housing condi-
tions and to relieve child poverty. Although this
argument could equally be applied to other medical
procedures, such as heart transplants, commercial
genetic testing is less likely to be a matter of life and
death and more likely to be another health check for
the aZuent, the worried and the hypochondriac.
IT IS IMPORTANT FOR INDIVIDUALS/FAMILIES TO
HAVE THE OPPORTUNITY TO BE INFORMED
There is an assumption that information is empow-
ering but to know you have a late onset untreatable
condition or a predisposition to a condition where
treatment is uncertain may not be. Ability to
predict a disease long before there are any
symptoms is what is attractive about the technology
but it creates a group of people who are “in an
ambiguous position between health and disease”
with implications for their life chances, including
their insurability and employability.14 Students sup-
ported choice in theory but when asked about spe-
cific tests most did not support over the counter
testing for everything and a minority rejected some
tests altogether. While 90 per cent agreed that
“people should be free to make up their own minds
about having a genetic test”, 82 per cent supported
at least some tests being available only through the
health service and 35 per cent felt that a test to find
the sex of an unborn child should not be available at
all. While the argument stresses the “opportunity”
to be informed, it may be diYcult to reject testing,
especially in pregnancy, or information may be
forced on someone by the actions of other family
members. “If everyone is getting tested then I have
to be tested too”.15
There is also the problem of the quality of the
information received. Despite the information
given in the questionnaire that most tests for carrier
status “are not 100% accurate, for example in the
test for cystic fibrosis carriers, only the most
common mutations are included”, a quarter of stu-
dents expected that a test “would detect 100% of
aVected individuals”. The more serious the impli-
cations of the test, the more accurate students
expected it to be. Nearly half the students (46%)
expected a test to see if their unborn child would
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have a genetic disorder to be completely accurate. It
is likely that counselling services would be available
with commercial tests but these are less likely to be
compulsory before the test will be given, for exam-
ple, a telephone advice line and written information
may be on oVer rather than a compulsory pretest
meeting with a genetic counsellor. While people
may be attracted by the privacy of the tests this does
not mean they are prepared for a “bad” result or for
information that is proved later to have been
inaccurate.
NEW TECHNOLOGY SOON BECOMES ROUTINISED
Tests for Down’s syndrome are routinely oVered to
older expectant mothers but this does not mean
they are now uncontroversial. Chris Goodey and
colleagues commented in the Bulletin of Medical
Ethics that the medical press concentrates on the
techniques of screening, which diverts attention
from the question “why screen for Down’s
syndrome, on what evidence and logic are the
arguments which support screening based” (for
example assumptions that Down’s syndrome in-
volves suVering).16 Technology may become routine
but this does not necessarily mean the ethical and
social issues have disappeared or been resolved.
Acceptable and unacceptable practices are as-
sumed to be easily distinguishable and supporters
of testing pick on clear-cut examples to make their
point. For example, the director of the Genetic
Interest Group wrote: “Pro-life groups believe that
the increased use of antenatal genetic testing will
lead to a dramatic increase in the number of abor-
tions carried out for trivial imperfections, such as
hair or eye colour”.17 This invites the (presumably
intended) response: “how ridiculous, no one would
do that”, particularly as pro-life groups are seen by
many in the UK as extremists. However, the public
recognise the existence of a large “gray area”
around research and practice and the diYculties of
“drawing the line”.18 While there is no problem in
“drawing the line” at aborting for eye and hair col-
our what about cystic fibrosis, cleft palate or
achondroplasia?
Professional and expert discourse in the
new genetics
The rhetoric surrounding the use of genetic
technology in health is that of individual choice or
consent from an informed position. Promoters of
commercial screening use this rhetoric to argue that
over the counter and mail order gene tests add to
the choices for individuals and families. The stress
on choice is used to deflect criticism of social engi-
neering and eugenics because the public, not the
state, will be in control. When I met with three rep-
resentatives of the diagnostic industry to present
the survey findings, they emphasised their role as
oVering the opportunity for testing but said that it
was up to society to decide whether tests should be
available to the public. In fact, however, the
diagnostic industry has a major influence on policy
in the UK. The industry’s representative on the
advisory committee on genetic testing was one of
the four members of a subgroup which produced
the Code of Practice and Guidance on Human Genetic
Testing Services Supplied Directly to the Public.19
This code of practice addresses social and ethical
issues and recommends, for example, that tests
should not be supplied to those under 16, and that
suppliers should provide “full information” and
opportunities for “pre and post test genetic consul-
tation [with] no additional charge” and should
obtain written consent to supply a copy of test
results to the customer’s GP.20 Genetic tests can be
said to be subject to a code of practice and fears of
unrestrained commercial testing allayed. Thus
individual tests gain an ethical gloss while the more
fundamental questions of the commercialisation of
genetic testing have not been tackled. The ques-
tions to be debated include: how far “drawing the
line in genetic testing” can be left to individual
“choice”; what constitutes “normality” and suVer-
ing; how the availability of a test for a condition
might aVect those who have the condition, and how
far people can be said to make a choice when they
are dependent on expert information and subject to
social pressures.
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